<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130127</url>
  </required_header>
  <id_info>
    <org_study_id>TERLIPRESSIN-LC</org_study_id>
    <nct_id>NCT03130127</nct_id>
  </id_info>
  <brief_title>Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis</brief_title>
  <official_title>Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis: A Prospective Non-randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Terlipressin is the mainstay drug for the treatment of acute variceal bleeding in liver
      cirrhosis. According to the drug instructions, intravenous bolus infusion is the standard
      approach of terlipressin. It remains unclear about whether or not continuous infusion of
      terlipressin should be considered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although intravenous bolus infusion of terlipressin is the standard approach, continuous
      infusion of terlipressin is preferred in clinical practice. The present study is a pilot
      non-randomized controlled trial to explore the feasibility and safety of continuous infusion
      of terlipressin for the treatment of acute variceal bleeding in liver cirrhosis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5 day treatment failure</measure>
    <time_frame>5 days (120 hours)</time_frame>
    <description>Death, fresh hematemesis, hypovolaemic shock, or 3 g drop in Hb (9% drop of Ht) within any 24 h period if no transfusion is administered.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Six-week mortality</measure>
    <time_frame>6 weeks</time_frame>
    <description>Death with 6 weeks after treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events related to terlipressin [Safety]</measure>
    <time_frame>5 days after treatment</time_frame>
    <description>Adverse events related to terlipressin, such as hyponatremia, diarrhea, abdominal pain, arterial hypertension, etc.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <condition>Variceal Hemorrhage</condition>
  <condition>Bleeding</condition>
  <condition>Esophageal and Gastric Varices</condition>
  <arm_group>
    <arm_group_label>Continuous infusion of terlipressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In our clinical practice, continuous infusion of terlipressin is being employed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bolus infusion of terlipressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Traditionally, a bolus infusion of terlipressin is recommended.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>According to the current practice guidelines and consensus, terlipressin is the standard treatment option for acute variceal bleeding in liver cirrhosis.</description>
    <arm_group_label>Continuous infusion of terlipressin</arm_group_label>
    <arm_group_label>Bolus infusion of terlipressin</arm_group_label>
    <other_name>Glypressin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A diagnosis of liver cirrhosis;

          2. Child-Pugh B or C;

          3. Acute gastroesophageal variceal bleeding;

          4. Written informed consents. -

        Exclusion Criteria:

          1. No liver cirrhosis;

          2. Child-Pugh class A;

          3. Acute upper gastrointestinal bleeding unrelated to varices;

          4. Use of somatostatin or octreotide. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaozhong Guo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Shenyang Military Area</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xingshun Qi, MD</last_name>
    <phone>86-18909881019</phone>
    <email>xingshunqi@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaozhong Guo, MD</last_name>
    <phone>86-024-28897613</phone>
    <email>guo_xiao_zhong@126.com</email>
  </overall_contact_backup>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2017</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Xingshun Qi</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

